Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 596

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 596
---
 will consist of a number of shares of FutureTech II common stock, par value $0.0001) equal to (a) (i) $100,000,000 minus (ii) the value of each outstanding option (whether vested or unvested) to purchase Longevity Common Stock that is converted into a new FutureTech II options in accordance with the Merger Agreement, divided by (b) $10.00.

The consummation of the FutureTech II Merger Transactions are subject to the satisfaction or waiver of certain customary closing conditions contained in the FutureTech II Merger Agreement, including, among other things, requisite approval by FutureTech II’s shareholders.

Note 9 - Subsequent Events

The Company has evaluated subsequent events through February 14, 2025, in connection with the preparation of these financial statements, which is the date the financial statements were available to be issued.

| F-76 |

<div align='center'>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

To the Members and Board of Directors of

Aegeria Soft Tissue LLC

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Aegeria Soft Tissue LLC (the “Company”) as of December 31, 2023 and 2022, the related statements of operations, changes in members’ deficit and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial